Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 73

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 73
---
 applicable requirements of Nasdaq. In arriving at this determination, our board of directors has examined each Audit Committee member’s scope of experience and the nature of their experience reading and understanding financial statements. The Audit Committee’s main function is to oversee our accounting and financial reporting processes and the audits of our consolidated financial statements. The Audit Committee’s responsibilities include, among other things: •selecting a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; •helping to ensure the independence and performance of the independent registered public accounting firm; •discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our annual audited financial statements and quarterly financial statements; 39 •developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; •reviewing and discussing policies on risk assessment and risk management; •reviewing related party transactions; •obtaining and reviewing a report by the independent registered public accounting firm at least annually that describes the internal quality -controlprocedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and •approving (or, as permitted, pre -approving) all audit and all permissible non -auditservice to be performed by the independent registered public accounting firm. Compensation Committee The members of our Compensation Committee are Ms. LaPorte, Dr. Rolfe and Mr. Patel. Ms. LaPorte serves as the chairperson of the Compensation Committee. Our board of directors has determined that each of Ms. LaPorte, Dr. Rolfe and Mr. Patel is independent under the applicable Nasdaq listing standards and is a “non -employeedirector” as defined in Rule 16b -3promulgated under the Exchange Act. Our Compensation Committee’s main function is to oversee our compensation structure, policies and programs and to review the processes and procedures for the consideration and determination of director and executive compensation. The Compensation Committee’s responsibilities include, among other things: •recommending to the board of directors goals and objectives, non -equitycompensation, and equity grants of all senior officers; •recommending to the board of directors goals and objectives, non -equitycompensation, and equity grants for the Chief Executive Officer; •recommending to the board of directors non -equitycompensation and equity grants for the directors; •reviewing and discussing with the board of directors corporate succession plans